Soligenix, Inc. · NASDAQ:SNGX
Soligenix — Investor Presentation (August 2015)
29 slides from Soligenix's investor presentation, Aug 31, 2015
Slide 1: Soligenix
((SOLIGENIX OTC QB: SNGX
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products a
Slide 3: Company Highlights
Company Highlights • Diversified product portfolio in advanced development, targeting rare disease indications in inflammation, oncology and biodefense with $200M+ markets worldwide o Phase 3 clinical program for the treatment of cutaneous T-cell lymphoma (SGX301) - Orphan drug and fast track design
Slide 4: Rare Disease Pipeline
Rare Disease Pipeline BioTherapeutics Product Candidates Preclinical Phase 1 Phase 2 Phase 3 Market SGX301 ORPHAN & FAST TRACK DESIGNATIONS Ph. 3 data 2H 2016* Cutaneous T-Cell Lymphoma (CTCL) SGX203 Ph. 3 data 2H 2017* ORPHAN & FAST TRACK DESIGNATIONS Pediatric Crohn’s Disease** SGX942 FAST TRACK D
Slide 5: Multiple Potential Value Drivers
Multiple Potential Value Drivers 2014 2015 2016 SGX301 FDA clearance 1H: EU orphan 2H: Ph. 3 start 2H: Ph. 3 data Ph. 3 study drug designation in CTCL in CTCL SGX942 NIH SBIR 1H: DRC positive 2H: Ph. 2 data in 2H: Ph. 3 start in grant award recommendation Oral Mucositis Oral Mucositis 1H: FDA cleara
Slide 6: Significant WW Market Potential
Significant WW Market Potential $500+ $500 Assumptions(1) 500 Oral Mucositis in H&N Cancer $450 450 90,000 Patients US 90,000 Patients EU 400 Cutaneous T-Cell Lymphoma 20,000 Patients US 350 $ Millions 20,000 Patients EU $300 Pediatric Crohn’s Disease 300 80,000 Patients US $250 80,000 Patients EU 2
Slide 7: Experienced Management and Board of Directors
Experienced Management and Board of Directors • 26 years of experience • Discovery Laboratories (COO) Christopher J. • Acute Therapeutics (Co-Founder) Keith Brownlie, • 35 years of experience Schaber, PhD CPA • Ernst & Young President & CEO • Ohmeda Pharmaceuticals • The Liposome Company • Wyeth Aye
Slide 8: BioTherapeutics
BioTherapeutics Targeted Approach to Treating Oncology & Inflammation 8
Slide 9: BioTherapeutics Business Segment
BioTherapeutics Business Segment Commercial targets – unmet medical needs in oncology and inflammation Cutaneous T-Cell Oncology SGX301 Lymphoma Oral Mucositis in SGX942 Head & Neck Soligenix Cancer BioTherapeutics Oncology Supportive Care Segment Oral BDP Acute Radiation (SGX201) Enteritis Autoimmu
Slide 10: SGX301 – Synthetic Hypericin
SGX301 – Synthetic Hypericin • First-in-class, represents new treatment paradigm – safe, visible light activates topical SGX301 (synthetic hypericin) to treat disease o Hypericin is one of the most powerful photosensitizers in nature o Established mechanism - Generation of singlet oxygen and apoptos
Slide 11: Cutaneous T-Cell Lymphoma (CTCL)
Cutaneous T-Cell Lymphoma (CTCL) • Class of Non-Hodgkin's Lymphoma (NHL) • Caused by a mutation of T-cells o Most NHLs are B-cell related o Malignant, skin-trafficking T-cells are recruited to the upper dermis and epidermis (by virtue of expression of high levels of the chemokine receptor CCR4) Over
Slide 12: SGX301 for CTCL
SGX301 for CTCL • First-in-class, proprietary composition represents new treatment paradigm – visible light with topical synthetic hypericin (skin-directed therapy) • Phase 1 study in healthy volunteers demonstrated safety and tolerability Phase 1 & 2 • Phase 2 double-blind, placebo-controlled, mult
Slide 13: SGX301 – Phase 2 Response Rate
SGX301 – Phase 2 Response Rate Summary of CTCL Lesion Responses to Synthetic Hypericin Ointment Following Six Weeks of Treatment Responders/Totala Percent Respondersa All Hypericin Responders 7/12 58.3%b Hypericin 0.25% Dose 5/9c 55.6%b Hypericin 0.1% Dose 5/12 41.7%b Placebo Responder 1/12 8.3% Not
Slide 14: Clinical Efficacy Before and After – SGX301 and Visible Light
Clinical Efficacy Before and After – SGX301 and Visible Light CTCL Patch Hypericin Therapy CTCL Patch Pre-Therapy Using Visible Light Post -Therapy 14
Slide 15: SGX94: Regulating the Innate Defense System
SGX94: Regulating the Innate Defense System • First responder to infection and tissue injury Innate o Mobilizes anti-infective and tissue healing factors Immunity o Mobilizes adaptive immunity o May cause excessive inflammatory response • Synthetic 5 amino acid Innate Defense Regulator (IDR) targeti
Slide 16: Oral Mucositis – Multi-Factorial Disease
Oral Mucositis – Multi-Factorial Disease • Debilitating side effect of cancer chemotherapy and / or radiotherapy o Massive ulceration of the mouth, tongue, soft palate and oropharynx Mucositis o Results in severe pain, inability to eat, reduced cancer treatment tolerance and significant increases in
Slide 17: Radiation-Induced Mucositis
Radiation-Induced Mucositis GOLD STANDARD Animal Model of Mucositis related to H&N Cancer • Decreased duration of mucositis by ~50% • Decreased peak severity from 3.4 to 3.0 % Days Score of >/= 3 P < .001 Oral Mucositis Induced in Hamsters by Fractionated Radiation – GOLD STANDARD • On study days 0,
Slide 18: Chemo-Induced Mucositis
Chemo-Induced Mucositis PROTECTS against chemotherapy damage PROTECTS ALL mucosal tissue Duration of Severe Oral Mucositis Clinical Endoscopy Score %Animals Days with a Score 3 25 M ean Endoscopy Colitis Score (+/-SEM ) Day 4 Day 7 2.0 20 53% reduction 1.5 15 p<.001 10 1.0 p<.05 5 0.5 0 0.0 VEHICL
Slide 19: SGX942 for Oral Mucositis
SGX942 for Oral Mucositis • Proprietary composition administered as 4-min IV infusion – short plasma half-life, rapid tissue penetration and prolonged pharmacodynamic impact • Phase 1 single and multiple ascending dose, double-blind, placebo-controlled study Phase 1 in 84 healthy volunteers o Safe a
Slide 20: SGX942 – Other Development Targets
SGX942 – Other Development Targets Multiple potential targets in infectious disease and biodefense with opportunity for non-dilutive funding to support development Target Potential Applications Potential Summary and Potential Indications Funding Next Steps Melioidosis Biodefense – Category B; NIH, D
Slide 21: Oral Beclomethasone 17,21-Dipropionate
Oral Beclomethasone 17,21-Dipropionate • SGX201, SGX203 and OrbeShieldTM are all independent product opportunities based on our orally administered proprietary formulation technology with beclomethasone 17,21-dipropionate (BDP) o Each enables potent, topical corticosteroid effect to treat GI inflamm
Slide 22: SGX203 for Pediatric Crohn's Disease
SGX203 for Pediatric Crohn’s Disease • Two tablet proprietary formulation of immediate and delayed release BDP Overview o Designed to treat inflammation throughout the GI tract o Positioned as a corticosteroid option with less toxicity than the current standard systemic steroid therapy – prednisone
Slide 23: Vaccine/BioDefense
Vaccine/BioDefense Addressing Critical Concerns for Industry and Government 23
Slide 24: Vaccine/BioDefense Business Segment
Vaccine/BioDefense Business Segment Infectious Disease Vaccines ThermoVaxTM Heat Stabilization Platform BioDefense Vaccines RiVaxTM Ricin Vaccine Soligenix BioDefense Vaccine / BioDefense Vaccines Segment* VeloThraxTM Anthrax Vaccine * Funded by Government OrbeShieldTM Gastrointestinal Acute (Oral B
Slide 25: ThermoVax – Vaccine Thermostability Platform
ThermoVaxTM – Vaccine Thermostability Platform • Dried vaccine with desirable physical and immunogenic properties • Improved stability and shelf-life at temperatures exceeding 40ºC o Positive Proof of Concept (POC) – 1 year stability data with no degradation • Preservation of native protein structur
Slide 26: RiVax – Ricin Toxin Vaccine
RiVaxTM – Ricin Toxin Vaccine • Produced as aluminum-adsorbed vaccine o Efficacy against all routes of toxin exposure • Statistically significant (p<0.0001) survival versus controls in non-human primate (NHP) lethal ricin toxin aerosol exposure model o 100% protection against ricin toxin Overview o
Slide 27: OrbeShield for GI ARS
OrbeShieldTM for GI ARS • Proprietary two tablet immediate and delayed release BDP formulation o Multiple commercial scale cGMP batches manufactured with long-term controlled room temperature stability Overview • Statistically significant survival post radiation exposure versus controls in canine mo
Slide 28: Investment Highlights
Investment Highlights • Diversified product portfolio in advanced development, targeting rare disease indications in inflammation, oncology and biodefense with $200M+ markets worldwide o Phase 3 clinical program for the treatment of cutaneous T-cell lymphoma (SGX301) - Orphan drug and fast track des
Slide 29: Thank You
THANK YOU www.soligenix.com